研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

组蛋白去甲基化酶 KDM1A 通过增加 NAFLD 中染色质的可及性来促进肝脏脂肪变性和炎症。

Histone demethylase KDM1A promotes hepatic steatosis and inflammation by increasing chromatin accessibility in NAFLD.

发表日期:2024 Jan 29
作者: Zifeng Yang, Siyao Zhang, Xiang Liu, Rui Shu, Wei Shi, Weiyi Qu, Dianyu Liu, Zhiwei Cai, Ye Wang, Xu Cheng, Yemao Liu, Xiao-Jing Zhang, Lan Bai, Hongliang Li, Zhi-Gang She
来源: JOURNAL OF LIPID RESEARCH

摘要:

非酒精性脂肪性肝病(NAFLD)是最常见的慢性肝病,没有特定的食品和药物管理局批准的药物。最近的进展表明染色质重塑和表观遗传改变有助于 NAFLD 的发展。然而,NAFLD 中相应分子调节剂的功能仍然难以捉摸。 KDM1A,通常称为赖氨酸特异性组蛋白去甲基化酶 1,据报道可增加肝细胞癌中的葡萄糖摄取。此外,最近的一项研究表明,抑制 KDM1A 可以减少原代棕色脂肪细胞中的脂质积累。我们在此研究了 KDM1A(最重要的组蛋白去甲基酶之一)在 NAFLD 中的作用。在这项研究中,我们观察到与对照组相比,NAFLD 小鼠、猴子和人类的 KDM1A 显着上调。基于这些结果,我们进一步发现KDM1A可以加剧肝细胞和小鼠的脂质积累和炎症。从机制上讲,KDM1A通过提高染色质可及性发挥作用,从而促进NAFLD的发展。此外,KDM1A 的突变削弱了其促进 NAFLD 发展的能力。总之,我们的研究发现 KDM1A 通过增加染色质可及性而加剧 NAFLD 中的肝脏脂肪变性和炎症,进一步表明利用染色质重塑和表观遗传改变在对抗 NAFLD 中的重要性。 KDM1A 可能被认为是这方面的潜在治疗靶点。版权所有 © 2024 作者。由爱思唯尔公司出版。保留所有权利。
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease without specific Food and Drug Administration-approved drugs. Recent advances suggest that chromatin remodeling and epigenetic alteration contribute to the development of NAFLD. The functions of the corresponding molecular modulator in NAFLD, however, are still elusive. KDM1A, commonly known as lysine-specific histone demethylase 1, has been reported to increase glucose uptake in hepatocellular carcinoma. In addition, a recent study suggests that inhibition of KDM1A reduces lipid accumulation in primary brown adipocytes. We here investigated the role of KDM1A, one of the most important histone demethylases, in NAFLD. In this study, we observed a significant upregulation of KDM1A in NAFLD mice, monkeys, and humans compared to the control group. Based on these results, we further found that the KDM1A can exacerbate lipid accumulation and inflammation in hepatocytes and mice. Mechanistically, KDM1A exerted its effects by elevating chromatin accessibility, subsequently promoting the development of NAFLD. Furthermore, the mutation of KDM1A blunted its capability to promote the development of NAFLD. In summary, our study discovered that KDM1A exacerbates hepatic steatosis and inflammation in NAFLD via increasing chromatin accessibility, further indicating the importance of harnessing chromatin remodeling and epigenetic alteration in combating NAFLD. KDM1A might be considered as a potential therapeutic target in this regard.Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.